Loading...

Amyris Inc
NASDAQ:AMRS

Watchlist Manager
Amyris Inc Logo
Amyris Inc
NASDAQ:AMRS
Watchlist
Price: 1.83 USD +2.81% Market Closed
Updated: Dec 6, 2022

Intrinsic Value

The intrinsic value of one AMRS stock under the Base Case scenario is 5.3 USD. Compared to the current market price of 1.83 USD, Amyris Inc is Undervalued by 65%.

The Intrinsic Value is calculated as the average of the two valuation methods:

AMRS Intrinsic Value
Base Case
5.3 USD
Undervaluation 65%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

AMRS Profitability Score
Profitability Due Diligence

Amyris Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.

Negative 3-Year Average ROIC
Negative Free Cash Flow
Negative Operating Income
Negative Net Income
49/100
Profitability
Score

Amyris Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.

AMRS Solvency Score
Solvency Due Diligence

Amyris Inc's solvency score is 25/100. The higher the solvency score, the more solvent the company is.

Low Interest Coverage
Low Altman Z-Score
Positive Net Debt
Long-Term Liabilities
25/100
Solvency
Score

Amyris Inc's solvency score is 25/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
11%
Gross Margin
-206%
Operating Margin
-132%
Net Margin
-271%
FCF Margin
132%
ROE
-109%
ROIC
Other

AMRS Capital Structure
Amyris Inc

Market Capitalization 595M USD
Total Debt 726M USD
Minority Interest 17.8M USD
Preferred Equity 0 USD
Cash and Equivalents 18.5M USD
Short-Term Investments 0 USD
Enterprise Value 1.3B USD

Wall St
Price Targets

AMRS Price Targets Summary
Amyris Inc

Wall Street analysts forecast AMRS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AMRS is 8.05 USD with a low forecast of 2.02 USD and a high forecast of 23.1 USD.

Lowest
Price Target
2.02 USD
10% Upside
Average
Price Target
8.05 USD
340% Upside
Highest
Price Target
23.1 USD
1 162% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

AMRS Competitors
Amyris Inc

AMRS Suppliers & Customers
Amyris Inc

There is no information about
Amyris Inc
key suppliers

Ownership

AMRS Insider Trading
Buy and sell transactions by insiders

Amyris Inc insiders have sold more shares than they have bought in the past 12 months.

During the last 12 months Amyris Inc insiders bought 168k USD , and sold 15M USD worth of shares. The last transaction was made on Dec 6, 2022 by Kung Frank (Director), who sold 128k USD worth of AMRS shares.

Sold
0-3
months
14.5M USD
1
3-6
months
440k USD
4
6-9
months
116k USD
3
9-12
months
0 USD
0
Bought
0-3
months
0
0 USD
3-6
months
1
69.1k USD
6-9
months
0
0 USD
9-12
months
No Insider Transactions
0
0 USD
Cumulative Transactions Amount
Period Sold Bought Net
3 Months
14.5M USD
N/A
-14.5M
6 Months
14.9M USD
69.1k USD
-14.9M
9 Months
15M USD
69.1k USD
-15M
12 Months
15M USD
69.1k USD
-15M
Purchases
58
Sales
177
Why is insider trading important?

Shareholder Return

AMRS Price
Amyris Inc

1M 1M
-29%
6M 6M
-21%
1Y 1Y
-69%
3Y 3Y
-44%
5Y 5Y
-45%
Annual Price Range
1.83
52w Low
1.52
52w High
6.62
Price Metrics
Average Annual Return 31.43%
Standard Deviation of Annual Returns 67%
Max Drawdown -93%
Shares Statistics
Market Capitalization 595M USD
Shares Outstanding 325 188 000
Percentage of Shares Shorted 20.75%

Company Profile

Amyris Inc

Country

United States of America

Industry

Chemicals

Market Cap

595M USD

Dividend Yield

0%

Description

Amyris, Inc. engages in the provision of bioscience solutions. The company is headquartered in Emeryville, California and currently employs 980 full-time employees. The company went IPO on 2010-09-28. The firm applies its Lab-to-Market biotechnology platform to engineer, manufacture and market high performance, natural and sustainably sourced products using its computational tools, strain construction tools, screening and analytics tools, and advanced lab automation and data integration. The firm's biotechnology platform enables users to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into high-value ingredients that it manufactures at industrial scale. Through the combination of its biotechnology platform and industrial fermentation process, the Company has developed, produced, and commercialized many distinct molecules. The firm is focused on three market areas, Health & Wellness, Clean Beauty and Flavor & Fragrance. Its brands include Biofene, Hemisqualane, Biossance, clean beauty skincare, Pipette, clean baby skincare and Purecane.

Contact

CALIFORNIA
Emeryville
5885 Hollis St Ste 100
+15104500761.0
https://www.amyris.com/

IPO

2010-09-28

Employees

980

Officers

Pres, CEO & Director
Mr. John G. Melo
CFO & Chief Admin. Officer
Mr. Hermanus Kieftenbeld
Chief Operating Officer
Mr. Eduardo Alvarez
Chief Legal Officer & Sec.
Ms. Nicole Kelsey
Chief Accounting Officer & Corp. Controller
Ms. Elizabeth E. Dreyer CPA
Sr. Director of Investor Relations & Corp. Communications
Mr. Peter DeNardo
Show More
Chief People Officer
Ms. Christine Ofori
Sr. VP of Global Manufacturing & Process Devel.
Mr. Charles Kraft
Pres of Aprinnova
Ms. Caroline Hadfield
Sr. VP of Nutrition Ingredients
Mr. Jim Iacoponi
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one AMRS stock?

The intrinsic value of one AMRS stock under the Base Case scenario is 5.3 USD.

Is AMRS stock undervalued or overvalued?

Compared to the current market price of 1.83 USD, Amyris Inc is Undervalued by 65%.